Recent evidence further indicates that VEGFR2 enhances CD8+ T-cell recruitment through activation of the PI3K/AKT/HIF-α pathway following anlotinib treatment in HCC (Song et al., 2024). The gene discussed is CD8A; the disease is hepatocellular carcinoma.